Sun Pharma Advanced Research Company Limited

BSE:532872 Stock Report

Market Cap: ₹67.8b

Sun Pharma Advanced Research Valuation

Is 532872 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 532872 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 532872's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 532872's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 532872?

Key metric: As 532872 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 532872. This is calculated by dividing 532872's market cap by their current book value.
What is 532872's PB Ratio?
PB Ratio-87.7x
Book-₹773.80m
Market Cap₹67.83b

Price to Book Ratio vs Peers

How does 532872's PB Ratio compare to its peers?

The above table shows the PB ratio for 532872 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average5.3x
AARTIPHARM Aarti Pharmalabs
3.1xn/a₹56.9b
SUPRIYA Supriya Lifescience
7x14.3%₹63.4b
524735 Hikal
4x49.2%₹47.6b
512529 Sequent Scientific
7.3xn/a₹49.4b
532872 Sun Pharma Advanced Research
n/an/a₹67.8b

Price-To-Book vs Peers: 532872 has negative equity and a Price-To-Book Ratio (-87.7x) compared to the peer average (5.3x).

Price to Book Ratio vs Industry

How does 532872's PB Ratio compare vs other companies in the IN Pharmaceuticals Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
0.6xn/aUS$66.29m
542678 Cian Healthcare
0.2xn/aUS$1.42m
524661 Welcure Drugs & Pharmaceuticals
0.1xn/aUS$1.29m
No more companies available in this PB range
532872 is unprofitableIndustry Avg. 3.5xNo. of Companies19PB02.44.87.29.612+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 532872 has negative equity and a Price-To-Book Ratio (-87.7x) compared to the Indian Pharmaceuticals industry average (3.5x).

Price to Book Ratio vs Fair Ratio

What is 532872's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

532872 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-87.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 532872's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

7D

0%

1Y

-45.9%

Sanofi India

₹142.5b

Manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.

SANOFI

₹6,197.45

7D

0.8%

1Y

-23.0%

Novartis India

₹26.1b

Operates as a healthcare company in India.

500672

₹1,058.30

7D

3.5%

1Y

52.4%